Center for Systems Biology and Molecular Medicine, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore 575018, India.
Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, United States.
J Proteome Res. 2021 May 7;20(5):2687-2703. doi: 10.1021/acs.jproteome.1c00008. Epub 2021 Apr 12.
Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related death worldwide. We showed previously that calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2), a serine-threonine kinase, is highly expressed in gastric cancer and leads to progression. In the present study, we identified the molecular networks involved in CAMKK2-mediated progression of gastric adenocarcinoma. Treatment of gastric cancer cell lines with a CAMKK2 inhibitor, STO-609, resulted in decreased cell migration, invasion, and colony-forming ability and a G1/S-phase arrest. In addition, tandem mass tag (TMT)-based quantitative proteomic analysis resulted in the identification of 7609 proteins, of which 219 proteins were found to be overexpressed and 718 downregulated (1.5-fold). Our data identified several key downregulated proteins involved in cell division and cell proliferation, which included DNA replication licensing factors, replication factor C, origin recognition complex, replication protein A and GINS, and mesenchymal markers, upon CAMKK2 inhibition. Immunoblotting and immunofluorescence results showed concordance with our mass spectroscopy data. Taken together, our study supports CAMKK2 as a novel therapeutic target in gastric cancer.
胃癌是全球第五大常见癌症,也是癌症相关死亡的第三大主要原因。我们之前曾表明,钙/钙调蛋白依赖性蛋白激酶激酶 2(CAMKK2)是一种丝氨酸/苏氨酸激酶,在胃癌中高度表达,并导致其进展。在本研究中,我们确定了涉及 CAMKK2 介导的胃腺癌进展的分子网络。用 CAMKK2 抑制剂 STO-609 处理胃癌细胞系,导致细胞迁移、侵袭和集落形成能力下降以及 G1/S 期停滞。此外,基于串联质量标签(TMT)的定量蛋白质组学分析鉴定了 7609 种蛋白质,其中 219 种蛋白质过表达,718 种蛋白质下调(1.5 倍)。我们的数据鉴定了几个关键的下调蛋白,这些蛋白涉及细胞分裂和细胞增殖,包括 DNA 复制许可因子、复制因子 C、起始识别复合物、复制蛋白 A 和 GINS,以及间充质标志物,这些蛋白在 CAMKK2 抑制后表达下调。免疫印迹和免疫荧光结果与我们的质谱数据一致。总之,我们的研究支持 CAMKK2 作为胃癌的一种新的治疗靶点。